Arcus Biosciences, INC Schedule 13G passive stakes

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Arcus Biosciences Inc. following an internal corporate realignment.

BlackRock, Inc. has reported an increased beneficial ownership of 10.4% in Arcus Biosciences Inc. common stock, holding 12,736,927 shares.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, reported a 4.1% beneficial ownership stake in Arcus Biosciences, Inc. as of September 30, 2025.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a passive beneficial ownership of 5.5% in Arcus Biosciences, Inc.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.4% passive beneficial ownership stake in Arcus Biosciences Inc. as of March 31, 2025.